

Genocea Biosciences Investor Relations Department 100 Acom Park Drive, 5th Floor Cambridge, MA 02140 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: GNCA	
Last Trade:	6.42
Trade Time:	1:00 PM ET Jul 25, 2017
Change:	0.59 † (+10.026%)
Day Range	6.22 - 6.78
52-Week Range	3.28 - 7.29
Volume	5,049,589

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... (more)

Stock Performance



Press Releases [View all]

Jul 24, 2017

Genocea Reports Positive Top-Line 12-Month
Phase 2b Data for GEN-003 in Genital
Herpes

Jun 26, 2017

Genocea Added to Russell 3000® and Russell 2000® Indices

May 4, 2017

Genocea Reports First Quarter 2017

Financial Results and Positive Clinical

Developments on Lead Candidate GEN-003

in Genital Herpes

Apr 27, 2017

Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET

Apr 11, 2017

Genocea Awarded World Vaccine Congress
2017 Industry Excellence Award for Best
Therapeutic Vaccine for GEN-003 for Genital
Herpes

Financials [View all]

First Quarter Financial Results

Feb 17, 2017 Annual Report (10-K)

Apr 21, 2017 Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 4, 2016 Quarterly Report (10-Q)

Aug 5, 2016
Quarterly Report (10-Q)